This approach proves more effective than standard CD20 monoclonal antibodies in models of B cell disorders, including non-Hodgkin lymphoma, systemic lupus erythematosus, and rheumatoid arthritis. The gene discussed is MS4A1; the disease is non-Hodgkin lymphoma.